What generic versions of Ivosidenib are available?

Ivosidenib (Ivosidenib) is an IDH1 inhibitor that belongs to an emerging class of targeted therapy drugs. Its main application area is the treatment of patients with acute myeloid leukemia (AML) who express IDH1 gene mutations, which are a common genetic abnormality in AML. Ivonib regulates the metabolic process in leukemia cells by specifically inhibiting the abnormal activity of IDH1 enzyme, thereby slowing down or preventing the uncontrolled growth of leukemia cells.

In the treatment of acute myeloid leukemia, ivonib has significant targeting properties by interrupting the abnormal metabolic pathways caused byIDH1 gene mutations. This specific effect is more precise than traditional chemotherapy, helping to reduce damage to normal cells and improve the safety of treatment.

Patients usually need to be tested for IDH1 gene mutations when taking ivonib to ensure that their genotype meets the indications of the drug. During treatment, doctors will design a personalized medication plan based on the patient's specific conditions and monitor regularly to evaluate efficacy and safety. In addition, the efficacy of ivonib may vary among different patients, so patients need to pay close attention to the treatment process under the guidance of their doctors and communicate in a timely manner about the treatment effects and any possible discomfort.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.